Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Piramal Pharma Limited ( (IN:PPLPHARMA) ) is now available.
Piramal Pharma Limited has been assigned an ESG Rating of ’61’ for the fiscal year 2023-24 by NSE Sustainability Ratings and Analytics Limited. This rating, which the company did not solicit, reflects the company’s performance in environmental, social, and governance aspects based on publicly available data. The rating could impact the company’s reputation and stakeholder perceptions regarding its commitment to sustainable practices.
More about Piramal Pharma Limited
Piramal Pharma Limited operates in the pharmaceutical industry, providing a range of pharmaceutical products and services. The company is focused on delivering high-quality healthcare solutions and has a significant presence in the market.
Average Trading Volume: 210,129
Current Market Cap: 267.6B INR
See more insights into PPLPHARMA stock on TipRanks’ Stock Analysis page.